Tiedote -

Philips to expand technology platforms for near patient diagnostic testing with acquisition of Unisensor

Amsterdam, the Netherlands and Allerød, Denmark – Royal Philips (NYSE: PHG; AEX: PHIA) today announced that it has signed an agreement to acquire Unisensor, an innovator in the field of optical analysis of fluids for diagnostic applications in health care, as well as other industries. The Unisensor technology and team will strengthen Philips’ innovation capabilities in the field of patient sample analysis such as blood testing for applications in oncology therapy monitoring. These innovations aim to enhance patient triage and treatment at the point-of-care (i.e. near the patient), thereby helping to improve patient care at a lower cost.

Upon closing of the transaction, which is expected in the third quarter of 2014 and subject to certain closing conditions, Unisensor, headquartered in Allerød, Denmark, will become part of Philips’ Healthcare Incubator within Philips Innovation, Group & Services. Financial terms of the acquisition were not disclosed.

“Philips’ Healthcare Incubator has already produced promising early-stage businesses in the area of near-patient testing and monitoring for the hospital and the home,” said Perry van Rijsingen, General Manager for Philips Healthcare Incubator. “The acquisition of Unisensor will expand our technology platforms for miniaturized, mobile diagnostic solutions and support our ambition to become a leader in this new growth market for Philips.”

Unisensor was founded in 1997 and is a privately held company with approximately 35 employees. Unisensor’s current product line includes oCelloScope, an analytical instrument that is, amongst other applications, used within cancer cell studies on a research application basis. The company has partnerships with leading companies in animal health and water analysis, which Philips intends to continue.

For further information, please contact:

Hans Driessen
Philips Healthcare Incubator
Tel.: +31 6 10610417
E-mail: hans.driessen@philips.com

Forward-looking statements

This release may contain certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.


Aiheet

  • Terveys, sairaanhoito, lääketiede

Kategoriat

  • mobile diagnostic solutions
  • acquisitions
  • patient diagnostic
  • innovation
  • philips healthcare
  • unisensor
  • healthcare incubator

Tietoa Royal Philips 

Royal Philips (NYSE: PHG, AEX: PHIA) on terveyden ja hyvinvoinnin alalla toimiva monialayritys, joka keskittyy parantamaan ihmisten elämänlaatua mielekkäiden innovaatioiden avulla terveydenhuollon, lifestyle-tuotteiden ja valaistuksen alalla.

 Yhtiön pääkonttori on Alankomaissa. Vuonna 2013 Philipsin palveluksessa työskenteli noin 113 000 henkilöä ja sen myynti oli 23,3 miljardia euroa. Yhtiöllä on myyntiä ja palveluita nykyisin yli 100 maassa. Philips on johtavassa asemassa kardiologisen hoidon, akuutti- ja kotihoidon, energiaa säästävien valaistusratkaisujen ja uudenlaisten valaistussovellusten sekä parranajon, muun kauneudenhoidon ja suun terveyden alalla. 

Yhteyshenkilöt

Anne-Cathrine Tjørnehøj

Lehdistön yhteyshenkilö Press Contact for Lighting Philips Lighting Tel: +45 403 308 06

Anna Ekholm

Lehdistön yhteyshenkilö Sr Marketing Specialist Healthcare Nordic +46 708322109

Liittyvä sisältö